 |
| February 28 |
QLT Announces Fourth Quarter and Year End 2013 Results  |
| |
|
| February 27 |
QLT Announces Positive Preliminary Results from Phase 1b Retreatment Trial of QLT091001 in Subjects with Leber Congenital Amaurosis and Retinitis Pigmentosa Due to Mutations in LRAT or RPE65 |
| |
|
| December 9 |
QLT Announces First Patient Dosed in Phase IIa Proof-of-Concept Trial for QLT091001 in Impaired Dark Adaptation |
| |
|
|
|
|
|
|
|
|
|
|
